Bank Of New York Mellon Corp Adagio Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	N/A	173,465 New	173,465 $208 Million
Q4 2022 Feb 14, 2023	BUY	$3.08 - $4.05 $539,803 - $709,807	175,261 New	175,261 $580,000
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $102,958 - $167,436	34,666 Added 24.61%	175,499 $549,000
Q2 2022 Aug 15, 2022	SELL	$2.54 - $4.52 $84,645 - $150,629	-33,325 Reduced 19.13%	140,833 $462,000
Q1 2022 May 11, 2022	BUY	$3.81 - $10.77 $405,464 - $1.15 Million	106,421 Added 157.11%	174,158 $794,000
Q4 2021 Feb 11, 2022	SELL	$6.35 - $47.04 $110,496 - $818,543	-17,401 Reduced 20.44%	67,737 $492,000
Q3 2021 Nov 12, 2021	BUY	$20.88 - $56.08 $1.78 Million - $4.77 Million	85,138 New	85,138 $3.6 Million

63.9M

2.3K

2.1K

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.